Conflict of interest in the debate over calcium-channel antagonists [1] (multiple letters)

New England Journal of Medicine

Volumn 338, Issue 23, 1998, Pages 1696-1698

  Meltzer, J I ^a   Opie, L ^a   Strandgaard, S ^a   Detsky, A ^a   Stelfox, H T ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LONG ACTING DRUG; NIFEDIPINE; VERAPAMIL;

CLINICAL TRIAL; CONFLICT; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; HUMAN; HYPERTENSION; LETTER; MEDICAL LITERATURE; PRIORITY JOURNAL; PUBLICATION; SIDE EFFECT; CONFLICT OF INTEREST; ECONOMICS; NOTE; PHYSICIAN; WRITING; PERSONNEL; CLASSIFICATION;

AUTHORSHIP; CALCIUM CHANNEL BLOCKERS; CONFLICT OF INTEREST; DRUG INDUSTRY; HUMANS; PHYSICIANS; RESEARCH SUPPORT; RESEARCH PERSONNEL;

EID: 0032482331     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199806043382313     Document Type: Letter

References (0)